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Background: End stage renal disease (ESRD) patients (pts) undergoing hemodialysis (HD) have an increased risk of ischemic as well as bleeding 
complications, the mechanisms of which remain poorly explored. The aim of this study was to evaluate thrombotic profiles of ESRD-HD pts.
Methods: Thromboelastography (TEG) assesses both cellular (platelets) and plasmatic (coagulation factors) components of thrombosis. TEG 
parameters assessed were: 1) maximum amplitude (MA): marker of platelet function and ischemic risk; 2) reaction time (R): marker of coagulation 
status and bleeding risk. Patients were classified as hyperaggregable (HA) if MA>69 mm and hypocoagulable (hC) if R>8 min.
Results: 70 pts were analyzed. Distribution of thrombotic profiles is shown in the Figure. 
Only 32.9% (n=23) had TEG parameters within normal limits. The remaining 67.1% (n=47) had an abnormality in MA, R, or in both: 18 (25.7%) were 
hC (R: 10.4±1.7min) with normal MA; 18 (25.7%) were HA (MA: 73.7±5mm) with normal R; 11 (15.7%) were both hC and HA (R: 11.5±3.3min; MA: 
72.5±3.1mm). Older age (71.6±11.7 vs. 58.6±11.7 years; p=0.005) and higher platelet count (253.7±55.4 vs. 191.7±74.4 x103/mm3; p=0.02) 
were associated with both hC and HA when compared to pts with normal values. No differences in antiplatelet therapy were observed between 
groups.
Conclusions: ESRD patients undergoing HD are frequently characterized by abnormal thrombotic profiles, which may contribute to their increased 
risk of ischemic as well as bleeding events.
